SIGA Technologies

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Earnings data Q3 2026

SIGA Technologies reports solid Q3 earnings amidst packaging challenges

SIGA Technologies is navigating packaging delays and inventory build-up while maintaining a strong financial position. Promising programs and trials indicate growth potential, with opportunities for additional orders and upsells in the EU market.

SIGA Technologies excels in Q4 2023 earnings, eyes innovation and growth

SIGA Technologies delivered impressive financial results in Q4 2023, with strong revenue growth and profitability. Despite facing challenges in contract extensions and manufacturing capacity, the company remains focused on innovation and expansion to drive future growth and value creation.

SIGA Technologies excels in Q1 2024, navigates health challenges

SIGA Technologies delivered a strong performance in Q1 2024, marked by revenue growth, operational efficiency, and strategic advancements. While maintaining a solid financial position, the company faces challenges related to public health concerns and regulatory complexities. Leveraging opportunities in product expansion and global partnerships will be key to sustaining growth and market leadership.

SIGA Technologies reports robust Q2 earnings and global expansion plans

SIGA Technologies' Q2 2024 performance reflects strong revenue growth and financial stability.
The company's focus on diversification, international expansion, and innovation positions it for future success.
Challenges in government contract negotiations and regulatory approvals are balanced by growth opportunities and positive outlook.

SIGA Technologies reports robust Q3 earnings and eyes global expansion

SIGA Technologies' Q3 2024 earnings call reflects strong financial performance, strategic partnerships, and a focus on innovation and market expansion.
The company's commitment to product safety, efficacy, and diverse revenue sources positions it well for future growth and sustained profitability.
While facing challenges in regulatory approvals and market competition, SIGA's financial stability, product credibility, and growth opportunities present a positive outlook.

SIGA Technologies reports robust 2024 performance amidst strategic challenges

SIGA Technologies' 2024 earnings call highlights a year of impactful execution and financial success. Despite challenges in clinical trials, the company maintains a strong balance sheet and strategic partnerships. With a focus on FDA submissions, fulfilling orders, and exploring diversification, SIGA is poised for growth. Ongoing discussions with key stakeholders and a commitment to product efficacy underscore the company's resilience.

SIGA Technologies reports robust Q1 performance and strategic growth outlook

SIGA Technologies' Q1 2025 performance reflects strong revenue generation, strategic initiatives, and financial stability amidst operational challenges. The company's focus on TPOXX programs, international growth, and collaborations with the U.S. government positions it for future growth opportunities. While facing operational losses and regulatory hurdles, SIGA's financial strength, product pipeline, and market positioning offer a foundation for long-term success.

SIGA Technologies reports robust Q2 earnings and navigates regulatory challenges

SIGA Technologies demonstrated strong financial performance in Q2 2025, driven by robust product sales and operational efficiency. While facing challenges with regulatory procedures and contract negotiations, the company's solid cash position and government support provide a foundation for future growth and innovation.

SIGA Technologies posts robust earnings, eyes growth amid regulatory reviews

SIGA Technologies demonstrates solid financial performance and operational efficiency in Q3 2025. While facing challenges like government disruptions and regulatory reviews, the company maintains strong revenue streams. Opportunities lie in program advancements, market expansions, and potential strategic initiatives for future growth.

SIGA reports Q1 losses but sees growth opportunities ahead

SIGA Technologies navigated Q1 2026 with a focus on smallpox preparedness and securing government contracts. Despite financial challenges, the company's international business growth and pipeline advancements offer promising opportunities. Addressing questions on product recommendations and capital deployment will be key for SIGA's future success and market expansion.

SIGA Technologies reports robust Q2 earnings, eyes new growth opportunities

SIGA Technologies (SIGA) delivered strong financial performance in Q2 2026, with $38 million in revenues and a solid balance sheet, reflecting operational resilience and growth potential. The company's focus on smallpox preparedness, international sales expansion, and ongoing product deliveries underpin its market presence and revenue diversification strategies. While facing global challenges and market competition, SIGA's engagement in new procurement contracts and strategic partnerships offers avenues for sustained growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.